Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

Related Keywords

Texas ,United States ,Katy Rezvani ,Sally Cooper Murray ,Research Institute Of Texas ,University Of Texas Md Anderson Cancer Center ,National Institutes Of Health ,Cancer Research ,Md Anderson Moon Shots Program ,Manderson Cancer ,Cancer Center ,Nature Medicine ,Stem Cell Transplantation ,New England Journal ,Sally Cooper Murray Endowed Chair ,National Institutes ,Cancer Prevention ,Research Institute ,Cell ,Ntigen ,Flood ,Dancer ,Chimeric Antigen Receptor ,Ytokine ,Lymphoma ,Manufacturing ,Medicine ,Eceptor ,Research ,Yndrome ,